Finding new drugs to block HIV protein interactions
Official title: Identification of HIV Rev-Rev interaction inhibitors by a high throughput, small molecule, cell-free screen
Funded at Yale University · NIH-10923198 · Data updated 2026-11-12
This study is looking for new small molecules that can help stop the HIV virus from making copies of itself, which could lead to better treatment options for people living with HIV, especially those who haven't had success with current medications.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | August 7, 2024 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $188,438 |
| NIH project number | 1R21AI181613-01A1 |
| Project ID | NIH-10923198 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals living with HIV who may benefit from new therapeutic options due to resistance or intolerance to current medications.
✕Less likely to help
Patients who are not infected with HIV or those who are already effectively managed on current antiretroviral therapies may not benefit from this research.
What this research studies
This research focuses on discovering new small molecules that can inhibit the interaction of the HIV Rev protein, which is crucial for the virus's ability to replicate. Using a high-throughput, cell-free screening method, the team will test various compounds to identify those that effectively disrupt this interaction. This approach aims to develop novel therapeutic options for HIV patients, particularly for those who may not respond well to existing treatments. By optimizing their assay system, the researchers hope to efficiently evaluate potential drug candidates in a laboratory setting.
Why it matters
Potential benefit: If successful, this research could lead to the development of new HIV treatments that are more effective and have fewer side effects.
How similar studies have gone: While there have been some compounds in clinical trials targeting HIV Rev, this specific approach using a cell-free screening method is relatively novel and has not been extensively tested.
Where this research is happening
-
Yale University
New Haven, United States Active
Researchers
- Principal investigator: Sutton, Richard — Yale University
- Study coordinator: Sutton, Richard
Related research
Other NIH-funded projects on the same topics.
-
Aging Well with HIV: Alcohol, Risk Reduction, and Education Center (AWAR3E)
A center at Yale is exploring how aging with HIV interacts with alcohol use to create inflammation and frailty, with the goal of finding biomarkers and potential treatments.
-
Community Health Worker–Led Hypertension Prevention and Control in Nepal
A community health worker–driven approach in Nepal aims to prevent and control high blood pressure among adults by bringing education and care directly to communities and homes.
-
Community health worker-led hypertension prevention and control in Nepal
A community health worker–led program in Nepal aims to help adults prevent and better control high blood pressure through home visits, education, and ongoing support.
-
Adapting a mobile health tool to boost HIV outcomes for older adults with HIV in Ukraine
A mobile health platform called PositiveLinks would be adapted for older adults with HIV in Ukraine to help them stay engaged in care and improve treatment success.
-
Behavioral and neural links between spoken language sounds and written words in young children
This grant studies how young children learn from listening and reading to improve literacy, by looking at how sound patterns transfer to written language.
-
Understanding how autoimmunity causes myasthenia gravis
This project looks at why the immune system attacks the nerve-muscle connection in myasthenia gravis and how different patient groups are affected.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.